相关实验视频

Updated: Jun 26, 2025

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

在初级结直肠癌中RAS/RAF突变和微卫星不稳定状态根据HER2放大结果

Sun Mi Lee^1,2, Hyunjoo Oh³

¹Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, 350 W. 11th Street, Indianapolis, IN, 46202, USA. drsunmi@yahoo.com.

Scientific reports

|May 19, 2024

概括

在结直肠癌 (CRC) 中的HER2放大与特定的分子特征有关. 这些HER2增强的CRC是微卫星稳定的,并表现出明显的突变模式,与未增强的瘤不同.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学是一个遗传学.

背景情况:

HER2放大是某些癌症的关键驱动因素,但其在结直肠癌 (CRC) 中的作用和相关分子特征仍然不清楚.
了解这些关联对于有针对性的治疗和改善CRC管理中的患者结果至关重要.

研究的目的:

确定HER2放大在一大群原发性结肠直肠癌 (CRCs) 的流行率.
调查与CRC中的HER2放大相关的临床病理特征和分子变化.
为了比较HER2增强型CRC与HER2不增强型CRC的分子格局.

主要方法:

追溯分析992例原发性结肠直肠癌 (CRC) 患者样本.
评估HER2放大和微卫星不稳定 (MSI) 状态.
下一代测序 (NGS) 用于分析HER2增强和未增强CRC中的体位突变.

主要成果:

在4.1%的CRC中检测到HER2放大,主要在左结肠和直肠.
HER2增强的CRC仅具有微卫星稳定性 (MSS).
与非增强型CRC相比,HER2增强型CRC的KRAS突变率较低 (24.4%),但TP53突变率较高 (83%). 没有发现BRAF或NRAS突变.

结论:

在结直肠癌中,HER2放大与微卫星稳定性有关.
HER2增强的CRC具有独特的分子形状,其特点是缺乏KRAS/NRAS/BRAF突变和频繁的TP53变异.
这些发现突出了HER2增强型CRCs作为一种独特的亚型,对向治疗策略有潜在的影响.

更多相关视频

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology

Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology

Published on: March 21, 2018

相关概念视频

The Ras Gene

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

MAPK Signaling Cascades

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...